Ixekizumab (4) – Taltz®

Plaque psoriasis (PP), ≥ 6 to < 18 years, body weight ≥ 25 kg

Characteristics

Start date 01.08.2020 – Marketing authorisation: 26.06.2020
Resolution 21.01.2021
INN Ixekizumab
Brand name Taltz®
Pharm. company Lilly Deutschland GmbH
G-BA Procedure ID D-570
ATC code L04AC13 Interleukin inhibitors (L04AC)
DDD 2.9 mg P
Therapeutic area Skin diseases
Reason for procedure New therapeutic indication
Specialty Bundling

Studies and Results

Children and adolescents aged 6 years and over with moderate to severe chronic plaque psoriasis and a body weight of at least 25 kg, who are eligible for systemic therapy

  • For children and adolescents aged 6 years and over with moderate to severe chronic plaque psoriasis and a body weight of at least 25 kg who are eligible for systemic therapy, the additional benefit of ixekizumab compared with the appropriate comparator therapy is not proven.
  • In its overall assessment, the G-BA therefore concludes that, for children and adolescents with moderate to severe plaque psoriasis, the additional benefit of ixekizumab compared with the appropriate comparator therapy is not proven.
  • Overall assessment
    • On balance, the G-BA therefore concludes that, for children and adolescents with moderate to severe plaque psoriasis, the additional benefit of ixekizumab compared with the appropriate comparator therapy is not proven.

Courtesy translation only, please refer to the German original.

Associated procedures



<< List of all resolutions